As part of the collaboration, Oxford will validate five novel oncology targets that were previously identified using the company's Oxford Genome Anatomy Project (OGAP) discovery platform and will generate antibodies against the targets. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.

Under the agreement, Oxford will receive an upfront payment of an undisclosed amount and will be eligible to receive additional payments based on the achievement of certain discovery, clinical, and regulatory milestones, as well as royalties on future potential sales.

Kite submits BLA for CAR T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel...

Kite to manufacture CAR T-cell therapy in Europe
Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European...